Citations

Clear

13 citation(s) found for "Srinath, BS".

Tumor-associated macrophage (TAM) score as an independent predictor of recurrence in residual disease after neoadjuvant chemotherapy and for identification of high-risk patients for adjuvant escalation.
Korlimarla, Aruna , S, Hari P, Krishna, Lohita, S, Chandana Sri, M, Sandhya Appachu, Veeraiyan, Durgadevi, Roy, Parinika Ajoy, Sulakshana, S , N, Ashitha N, Advani, Pooja , Srinath, BS, Kanyadhara, Lohita Krishna, Appachu, Sandhya , Srinath, B. S.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 522-522

10.1200/jco.2026.44.16_suppl.522 Get It

522 Background: Tumor-associated macrophages (TAMs) drive immune evasion and chemotherapy resistance in breast cancer through tumor microenvironment reprogramming. We developed a composite TAM score integrating transcriptional programs with spatial IHC polarization markers to stratify recurrence risk and enrich macrophage-modulating trials, hypothesizing it would improve prognostic accuracy in treatment-naïve disease and predict neoadjuvant chemotherapy (NACT) response. Methods: TAM score was derived from scRNA-seq atlases (n=4), filtering survival-associated genes in METABRIC/TCGA (n=2,509), and weighting IHC markers CD163/CD206 normalized to CD68/CSF1R via Cox coefficients. Validation: treatment-naïve invasive carcinomas (n=83; follow-up 57 months; 24 events). Primary endpoint: recurrence-free survival (RFS); multivariable Cox adjusted for age, tumor size, nodal status, grade, subtype, treatment. Predictive utility assessed in matched primary/post-NACT residual tumors (n=45) correlating TAM dynamics with RCB. Results: High TAM score (≥median) independently predicted worse RFS (HR 3.8, 95% CI 1.6-9.1, p<0.05) and outperformed CD163/CD68 alone (HR 2.1, p<0.05); 5-year RFS was 68% vs 91% (TAM-high vs TAM-low). Prognostic value persisted in node-negative (HR 4.2, p=0.02) and luminal B (HR 3.5, p=0.01) subsets. In the NACT cohort, baseline TAM score inversely correlated with pCR (12% vs 38%, p=0.04). Among residual disease (RCB-II/III, n=34), persistent TAM-high post-NACT identified 3-year RFS 52% vs 85% in TAM-low/normalized cases (HR 4.1, p=0.01), independent of RCB; CD163+/CD206+ expansion occurred in 76% of RCB-III vs 29% of RCB-I (p=0.008). Conclusions: This TAM score predicts recurrence from pre-treatment tissue and identifies macrophage-driven resistance persisting post-NACT, nominating TAM-high residual disease for macrophage-modulating trials. Translational evidence supports this: CSF1R inhibition reduced immunosuppressive TAMs, increased M1-like programs, decreased PD-L1/PD-L2, and enhanced anti-PD-1 efficacy preclinically with ex vivo confirmation. Early-phase data (rebastinib plus chemotherapy in HER2-negative metastatic disease) demonstrate feasibility, supporting prioritization of TAM-high patients with residual disease for trials combining TAM modulation with checkpoint therapy. TAM score performance in treatment-naïve and NACT cohorts. Endpoint TAM-High TAM-Low HR scores (95% CI) p-value Treatment Naïve cohort 5 year RFS (Overall) 68% 91% 3.8 (1.6-9.1) <0.05 RFS (node-negative) 4.0 0.02 RFS (luminal B)-- 3.5 0.01 CD163/CD68 alone 2.1 <0.05 NACT Cohort (n=45) Baseline pCR rate 12% 38%- 0.04 3-year RFS(RCB-II/III n=34) 52% 85% 4.1 0.01 CD163+/CD206+ expansion 76% (RCB-III) 29%(RCB-I)- 0.008
Current Trends and Future Prospects of Radiomics and Machine Learning (ML) Models in Spinal Tumors—A Narrative Review
Sanker, Vivek , Panchawgh, Suhrud, Kaur, Anmol, Suresh, Vinay , Mahesh, Dhanya, Ahmad, Eeman, Hariharan, Srinath, Pangal, Dhiraj J. , Cavgnaro, Maria Jose, Rusu, Mirabela , Ratliff, John K. , Suresh, Vinay , Ratliff, John , Kaur, Anmol , Hariharan, Srinath, Cavagnaro, María José , Desai, Atman

Mayo Clinic

Journal of Imaging | March 19, 2026 | Volume: 12 | Issue: 3 | Pages: 138

10.3390/jimaging12030138 | PMID 41892940 Get It

The intersection between radiomics, the computational analysis of imaging data, and machine learning (ML) may lead to new developments in the diagnosis, prognosis, and management of diseases. For spinal tumors specifically, applications of these fields appear promising. In this educational narrative review, we provide a summary of the current advancements in radiomics and artificial intelligence (AI), as well as applications of both fields in the diagnosis and management of spinal tumors. We also provide a suggested workflow of radiomics and machine learning analysis of spinal tumors for researchers, including a list and description of commonly used radiomic features. Future directions in the field of radiomics and machine learning applications to spinal tumors may involve validating already proposed algorithms with larger datasets, ensuring that all computational applications to patient care maintain high ethical standards, and continuing work in developing novel and highly accurate computational techniques to enhance patient outcomes.
Hypertension Pharmacological Treatment in Adults: A World Health Organization Guideline Executive Summary
Al-Makki, Akram , DiPette, Donald, Whelton, Paul K. , Murad, M. Hassan, Acharya, Shrish, Beheiry, Hind Mamoun, Champagne, Beatriz, Connell, Kenneth , Cooney, Marie Therese, Ezeigwe, Nnenna, Gaziano, Thomas Andrew , Gidio, Agaba, Lopez-Jaramillo, Patricio, Khan, Unab I., Kumarapeli, Vindya , Moran, Andrew E., Silwimba, Margaret Mswema, Sukonthasan, Apichard, Yu, Jing, Saraffzadegan, Nizal, Reddy, K. Srinath, Khan, Taskeen, Reddy, K. Srinath , Mustafa, Reem A , Connell, Kenneth , Gaziano, Thomas Andrew , Kumarapeli, Vindya , Rayner, Brian , Al-Makki, Akram , DiPette, Donald, Whelton, Paul K , Murad, M. Hassan, Acharya, Shrish, Beheiry, Hind Mamoun, Champagne, Beatriz, Cooney, Marie Therese , Ezeigwe, Nnenna, Gidio, Agaba, Lopez-Jaramillo, Patricio, Khan, Unab I., Moran, Andrew E., Silwimba, Margaret Mswema, Sukonthasan, Apichard, Yu, Jing, Saraffzadegan, Nizal, Reddy, K. Srinath, Khan, Taskeen

Mayo Clinic

Hypertension | November 15, 2021 | Volume: 79 | Issue: 1 | Pages: 293-301

10.1161/hypertensionaha.121.18192 | PMID 34775787 Get It

Hypertension is a major cause of cardiovascular disease and deaths worldwide especially in low- and middle-income countries. Despite the availability of safe, well-tolerated, and cost-effective blood pressure (BP)-lowering therapies, <14% of adults with hypertension have BP controlled to a systolic/diastolic BP <140/90 mm Hg. We report new hypertension treatment guidelines, developed in accordance with the World Health Organization Handbook for Guideline Development. Overviews of reviews of the evidence were conducted and summary tables were developed according to the Grading of Recommendations, Assessment, Development, and Evaluations approach. In these guidelines, the World Health Organization provides the most current and relevant evidence-based guidance for the pharmacological treatment of nonpregnant adults with hypertension. The recommendations pertain to adults with an accurate diagnosis of hypertension who have already received lifestyle modification counseling. The guidelines recommend BP threshold to initiate pharmacological therapy, BP treatment targets, intervals for follow-up visits, and best use of health care workers in the management of hypertension. The guidelines provide guidance for choice of monotherapy or dual therapy, treatment with single pill combination medications, and use of treatment algorithms for hypertension management. Strength of the recommendations was guided by the quality of the underlying evidence; the tradeoffs between desirable and undesirable effects; patient’s values, resource considerations and cost-effectiveness; health equity; acceptability, and feasibility consideration of different treatment options. The goal of the guideline is to facilitate standard approaches to pharmacological treatment and management of hypertension which, if widely implemented, will increase the hypertension control rate world-wide.
Diabetic ketoacidosis drives COVID‐19 related hospitalizations in children with type 1 diabetes
Alonso, G. Todd , Ebekozien, Osagie , Gallagher, Mary , Rompicherla, Saketh, Lyons, Sarah K. , Choudhary, Abha , Majidi, Shideh , Pinnaro, Catherina T. , Balachandar, Sadana, Gangat, Mariam , Marks, Brynn E. , Creo, Ana L. , Sanchez, Janine , Seeherunvong, Tossaporn, Jimenez‐Vega, Jose , Patel, Neha S. , Gabriel, Liana , Sumpter, Kathryn , Wilkes, Meredith , Rapaport, Robert , Cymbaluk, Anna, Wong, Jenise C. , Sanda, Srinath , Albanese-O’Neill, Anastasia , Alonso, Guy Todd , Creo, Ana , Wilkes, Meredith , Wong, Jenise C , Roberts, Alissa Jeanne Curda , Wood, Jamie

Mayo Clinic

Journal of Diabetes | April 15, 2021 | Volume: 13 | Issue: 8 | Pages: 681-687

10.1111/1753-0407.13184 | PMID 33855813 Get It

AbstractBackgroundDiabetes is a risk factor for poor COVID‐19 outcomes, but pediatric patients with type 1 diabetes are poorly represented in current studies.MethodsT1D Exchange coordinated a US type 1 diabetes COVID‐19 registry. Forty‐six diabetes centers submitted pediatric cases for patients with laboratory confirmed COVID‐19. Associations between clinical factors and hospitalization were tested with Fisher's Exact Test. Logistic regression was used to calculate odds ratios for hospitalization.ResultsData from 266 patients with previously established type 1 diabetes aged <19 years with COVID‐19 were reported. Diabetic ketoacidosis (DKA) was the most common adverse outcome (n = 44, 72% of hospitalized patients). There were four hospitalizations for severe hypoglycemia, three hospitalizations requiring respiratory support (one of whom was intubated and mechanically ventilated), one case of multisystem inflammatory syndrome in children, and 10 patients who were hospitalized for reasons unrelated to COVID‐19 or diabetes. Hospitalized patients (n = 61) were more likely than nonhospitalized patients (n = 205) to have minority race/ethnicity (67% vs 39%, P < 0.001), public insurance (64% vs 41%, P < 0.001), higher A1c (11% [97 mmol/mol] vs 8.2% [66 mmol/mol], P < 0.001), and lower insulin pump and lower continuous glucose monitoring use (26% vs 54%, P < 0.001; 39% vs 75%, P < 0.001). Age and gender were not associated with risk of hospitalization. Higher A1c was significantly associated with hospitalization, with an odds ratio of 1.56 (1.34‐1.84) after adjusting for age, gender, insurance, and race/ethnicity.ConclusionsHigher A1c remained the only predictor for hospitalization with COVID‐19. Diabetic ketoacidosis is the primary concern among this group.
A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH)
Girard, Romuald , Stadnik, Agnieszka , Shenkar, Robert , Hobson, Nicholas , Romanos, Sharbel , Srinath, Abhinav , Moore, Thomas , Lightle, Rhonda , Shkoukani, Abdallah , Akers, Amy , Christoforidis, Gregory A. , Lee, Cornelia , Piedad, Kristina , Greenberg, Steven M. , Kim, Helen , Flemming, Kelly D. , Awad, Issam A. , Girard, Romuald , Shenkar, Robert , Flemming, Kelly D , Kim, Helen , Li, Yan , Hobson, Nicholas, Carroll, Timothy , Koenig, James I. , Ji, Yuan

Mayo Clinic

Neurosurgery | October 1, 2020 | Volume: 88 | Issue: 3 | Pages: 686-697

10.1093/neuros/nyaa478 | PMID 33469662 Get It

Abstract BACKGROUND Cerebral cavernous angioma (CA) is a capillary microangiopathy predisposing more than a million Americans to premature risk of brain hemorrhage. CA with recent symptomatic hemorrhage (SH), most likely to re-bleed with serious clinical sequelae, is the primary focus of therapeutic development. Signaling aberrations in CA include proliferative dysangiogenesis, blood-brain barrier hyperpermeability, inflammatory/immune processes, and anticoagulant vascular domain. Plasma levels of molecules reflecting these mechanisms and measures of vascular permeability and iron deposition on magnetic resonance imaging are biomarkers that have been correlated with CA hemorrhage. OBJECTIVE To optimize these biomarkers to accurately diagnose cavernous angioma with symptomatic hemorrhage (CASH), prognosticate the risk of future SH, and monitor cases after a bleed and in response to therapy. METHODS Additional candidate biomarkers, emerging from ongoing mechanistic and differential transcriptome studies, would further enhance the sensitivity and specificity of diagnosis and prediction of CASH. Integrative combinations of levels of plasma proteins and characteristic micro-ribonucleic acids may further strengthen biomarker associations. We will deploy advanced statistical and machine learning approaches for the integration of novel candidate biomarkers, rejecting noncorrelated candidates, and determining the best clustering and weighing of combined biomarker contributions. EXPECTED OUTCOMES With the expertise of leading CA researchers, this project anticipates the development of future blood tests for the diagnosis and prediction of CASH to clinically advance towards precision medicine. DISCUSSION The project tests a novel integrational approach of biomarker development in a mechanistically defined cerebrovascular disease with a relevant context of use, with an approach applicable to other neurological diseases with similar pathobiologic features.
Incessant tachycardia after successful ablation of an atriofascicular pathway
Lahiri, Anandaroop , Roshan, John , Patloori, Sirish Chandra Srinath , Kapa, Suraj , Chase, David

Mayo Clinic

EP Europace | April 18, 2019 | Volume: 22 | Issue: 1 | Pages: 83-83

10.1093/europace/euz138 | PMID 31532480 Get It

Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma
DiNorcia, Joseph , Haydel, Brandy , Tabrizian, Parissa , Ruiz, Richard , Klintmalm, Göran B. , Senguttuvan, Srinath, Lee, David D. , Verna, Elizabeth C. , Halazun, Karim J. , Chapman, William C. , Vachharajani, Neeta , Aucejo, Federico , Nguyen, Mindie H. , Melcher, Marc L. , Tevar, Amit D. , Humar, Abhinav , Mobley, Constance M. , Ghobrial, R. Mark , Nydam, Trevor L. , Amundsen, Beth, Markmann, James F. , Berumen, Jennifer , Hemming, Alan W. , Langnas, Alan N. , Carney, Carol A., Sudan, Debra L. , Hong, Johnny C. , Kim, Joohyun , Zimmerman, Michael A. , Rana, Abbas , Kueht, Michael , Jones, Christopher M. , Fishbein, Thomas , Markovic, Daniela , Busuttil, Ronald W. , Taner, C. Burcin , Lee, David D , Melcher, Marc L , Halazun, Karim J , Chapman, William C , Sudan, Debra L , Florman, Sander , Hoteit, Maarouf , Levine, Matthew H , Agopian, Vatche G.

Mayo Clinic

Annals of Surgery | March 22, 2019 | Volume: 271 | Issue: 4 | Pages: 616-624

10.1097/sla.0000000000003253 | PMID 30870180 Get It

Objective: The aim of the study was to determine the rate, predictors, and impact of complete pathologic response (cPR) to pretransplant locoregional therapy (LRT) in a large, multicenter cohort of hepatocellular carcinoma (HCC) patients undergoing liver transplantation (LT). Background: LRT is used to mitigate waitlist dropout for patients with HCC awaiting LT. Degree of tumor necrosis found on explant has been associated with recurrence and overall survival, but has not been evaluated in a large, multicenter study. Methods: Comparisons were made among patients receiving pre-LT LRT with (n = 802) and without (n = 2637) cPR from the United States Multicenter HCC Transplant Consortium (UMHTC), and multivariable predictors of cPR were identified using logistic regression. Results: Of 3439 patients, 802 (23%) had cPR on explant. Compared with patients without cPR, cPR patients were younger; had lower Model for End-stage Liver Disease (MELD) scores, AFP levels, and neutrophil–lymphocyte ratios (NLR); were more likely to have tumors within Milan criteria and fewer LRT treatments; and had significantly lower 1-, 3-, and 5-year incidence of post-LT recurrence (1.3%, 3.5%, and 5.2% vs 6.2%, 13.5%, and 16.4%; P < 0.001) and superior overall survival (92%, 84%, and 75% vs 90%, 78%, and 68%; P < 0.001). Multivariable predictors of cPR included age, sex, liver disease diagnosis, MELD, AFP, NLR, radiographic Milan status, and number of LRT treatments (C-statistic 0.67). Conclusions: For LT recipients with HCC receiving pretransplant LRT, achieving cPR portends significantly lower posttransplant recurrence and superior survival. Factors predicting cPR are identified, which may help prioritize patients and guide LRT strategies to optimize posttransplant cancer outcomes.
A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.
Vaishampayan, Ulka N. , Matrana, Marc , Zurita, Amado J. , Keam, Bhumsuk , Sundararajan, Srinath , Mowat, Rex B., Dudek, Arkadiusz Z. , Gan, Lu , Vaishampayan, Ulka , McDermott, David F. , Rha, Sun Young , Ho, Thai H. , Lee, Jae‐Lyun , Joseph, Richard W. , Ali, Sarah, Stadler, Walter M. , Haas, Naomi B , Park, Se Hoon , Picus, Joel , Zakharia, Yousef , Atkins, Michael B. , Dudek, Arkadiusz Z

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4510-4510

10.1200/jco.2018.36.15_suppl.4510 Get It

Synovial osteochondromatosis of the elbow
Morrey, B.F., Kamineni, Srinath , O’Driscoll, Shawn W.

Mayo Clinic

The Journal of Bone and Joint Surgery. British volume | February 21, 2018 | Volume: 84-B | Issue: 7 | Pages: 961-966

10.1302/0301-620x.84b7.0840961 Get It

We present 12 patients with synovial osteochondromatosis of the elbow treated by synovectomy. Histological review showed that seven cases were primary and five secondary osteochondromatosis. The patients with primary disease had a mean improvement in the flexion arc from a preoperative value of 40° to 123° to 5° to 128° when reviewed at a mean of nine years after operation. The secondary group had a mean improvement in the flexion arc from a preoperative value of 21° to 98° to 4° to 131° at a mean of 6.8 years after operation. There was recurrence in two of seven patients in the primary group and three of five in the secondary group. Osteoarthritis developed in six elbows in the primary and in three in the secondary group. Osteoarthritis secondary to synovial osteochondromatosis is progressive. In the established condition, the distinction between primary and secondary disease may be of greater histological than clinical relevance.